Recent Publications
Duckworth K, Forti A, Russell G, Campbell C, Naik S, Hurd D, McQuellon R. Advance care planning information and distress in hematopoietic cell transplant candidates and proxies [abstract]. Psychooncology. 2013;22(Suppl 2):100-101.
Naik S, D'Agostino R Jr, Lamar Z, Graham RM, Vatca M, Agnew E, Higgins A, Levitan D, Hurd D. Outcomes of second transplants for disease recurrence or for myelodysplasia (MDS) developing after an initial transplant (Tx) [abstract]. Biol Blood Marrow Transplant. 2012;18(2 Suppl 2):S340-S341.
McQuellon R, Duckworth K, Campbell C, Russell G, Naik S, Levitan D, Zamkoff K, McQuellon BT, Hurd D. Fear of recurrence following hematopoetic stem cell transplantation [abstract]. Psychooncology. 2012;21(Suppl 1):127.
Wendtner C-M, Hillmen P, Mahadevan D, Buhler A, Uharek L, Coutre S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, et al.
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(3):417-423.
McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A,.
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-1781.
Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED.
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97(5):758-765.
High KP, Case D, Hurd D, Powell B, Lesser G, Falsey AR, Siegel R, Metzner-Sadurski J, Krauss JC, Chinnasami B, Sanders G, Rousey S, Shaw EG.
A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia. J Support Oncol. 2012;10(5):195-201.
Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Hurd DD, Blum KA, Goy A, Fenske TS, Cashen A, Wagner-Johnston ND, Carson KR, Bartlett NL. A phase 2 multicenter study of continuous dose lenalidomide in relapsed or refractory classical Hodgkin lymphoma [abstract]. Blood. 2012;120(21):Abstr 1623.
Loth K, Naik S, Kennedy LA, Levitan D, Zamkoff K, Hurd D. Infectious complications associated with the use of antithymocyte globulin in reduced intensity allogeneic transplants [abstract]. Biol Blood Marrow Transplant. 2011;17(2 Suppl 2):S355-S356.
Naik S, Shope D, Albright C, Graham R, Levitan D, Zamkoff K, D'Agostino R Jr, Hurd D. Transplant outcomes in multiple myeloma patients younger versus older than 60 years of age in the era of newer targeted agents [abstract]. Biol Blood Marrow Transplant. 2011;17(2 Suppl 2):S252-S253.
Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Hurd D, et al.
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011;35(3):329-333.
Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe L-A, Devine S, Farag S, Hurd D, Ball E, et al.
Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation:. Biol Blood Marrow Transplant. 2011;17(4):558-565.
Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung S-H, Peterson BA, Nadler LM, Freedman A, Hurd DD, et al.
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma. 2011;52(4):587-596.
Campbell C, McQuellon R, Duckworth K, Russell G, Hurd D, Levitan D, Naik S, Zamkoff K, McQuellon B, Sommer J. Health related quality of life, depressive symptoms and distress before and after hematopoietic cell transplantation [abstract]. Psychooncology. 2011;20(Suppl 1):81.
Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, et al.
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011;118(19):5119-5125.
Pardee T, DeFord-Watts LM, Peronto E, Levitan DA, Hurd DD, Kridel S. Altered lipid and mitochondrial metabolism are viable targets in acute leukemia [abstract]. Blood. 2011;118(21):1546.
Voorhees PM, Gasparetto C, Osman K, Richards KL, Ferraro M, Garcia R, MacLean J, Winans D, Moore D, Strader J, Orlowski RZ, Hurd DD. Vorinostat in combination with pegylated liposomal doxorubicin (PLD) and bortezomib (B) in patients with relapsed/refractory multiple myeloma (R/R MM): final results of a phase I study [abstract]. Blood. 2011;118(21):1705-1706.
Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Hurd DD, et al.
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. Int J Radiat Oncol Biol Phys. 2010;76(5):1305-1313.
McQuellon R, Campbell C, Russell G, Duckworth K, Sommer J, McQuellon B, Hurd D. Quality of survivorship, surveillance behavior and treatment satisfaction following hematopoietic cell transplantation [abstract]. Psychooncology. 2010;19(Suppl 1):S98-S99.
Ritter EM, Zamkoff KW, Levitan DA, Hurd DD. The importance of timing of hematopoietic stem cell transplantation (HSCT) in patients with T-cell lymphomas (T-NHL) [abstract]. Biol Blood Marrow Transplant. 2010;16(2 Suppl 2):S238.
McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hassoun H, Hurd DD, Stadtmauer EA, Giralt S, Hars V, Linker CA. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104 [abstract]. J Clin Oncol. 2010;28(15 Suppl Pt 1):577s.
McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Richardson PG, Levitan D, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma CALGB 100104 [abstract]. Blood. 2010;116(21):21-22.
Wendtner C, Hillmen P, Mahadevan D, Stilgenbauer S, Uharek L, Coutre S, Frankfurt O, Bloor A, Bosch F, Hurd DD, et al. Final results of the Phase I study of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL-001 Study) [abstract]. Blood. 2010;116(21):591-592.
Voorhees PM, Gasparetto C, Osman K, Richards K, Ferraro M, Garcia R, MacLean J, Winans D, Moore D, Hurd DD, et al. Results of a phase I study of vorinostat in combination with pegylated liposomal doxorubicin and bortezomib in patients with relapsed/refractory multiple myeloma [abstract]. Blood. 2010;116(21):815.
Danhauer SC, Vishnevsky T, Campbell CR, McCoy TP, Tooze JA, Kanipe KN, Arrington SA, Holland EK, Lynch MB, Hurd DD, Cruz J.
Music for patients with hematological malignancies undergoing bone marrow biopsy: a randomized controlled study of anxiety, perceived pain, and patient satisfaction. J Soc Integr Oncol. 2010;8(4):140-147.
Beaty MW, Pettenati M, Hurd DH [sic] [Hurd DD], Keung Y. Possible role of engraftment syndrome in myelodysplastic syndrome after autologous transplants [abstract]. Mod Pathol. 2009;22(Suppl 1):1161.
McClure White G, Campbell C, Russell G, Duckworth K, Hurd D, McQuellon R. Assessing distress and depression in hematopoietic stem cell transplant patients [abstract]. Psychooncology. 2009;18(Suppl 1):S43.
Wendtner CM, Mahadevan D, Coutre S, Hillmen P, Stilgenbauer S, Frankfurt O, Bloor A, Bosch F, Furman R, Hurd D, et al. A phase I dose-escalation of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. Haematologica. 2009;94(Suppl 2):371-372.
Storey JA, Connor RF, Lewis ZT, Hurd D, Pomper G, Keung YK, Lovato J, Torti SV, Torti FM, Molnar I, et al.
The transplant iron score as a predictor of stem cell transplant survival. J Hematol Oncol. 2009;2():article 44.
Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, LaCasce AS, Blum KA, Byrd JC, Kelly M, et al.
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27(36):6101-6108.
Smith SM, Johnson J, Cheson BD, Canellos G, Petroni G, Oken M, Duggan D, Hurd D, Gockerman JP, Parker B, et al.
Recombinant interferon-alpha 2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma. 2009;50(10):1606-1617.
McCarthy PL, Owzar K, Stadtmauer EA, Giralt S, Hurd DD, Hassoun H, Hofmeister C, Richardson P, Weisdorf DJ, Pasquini MC, et al. Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): initial report of patient accrual and adverse events [abstract]. Blood. 2009;114(22):1327.
Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, DiPersio JF, et al. A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma [abstract]. Blood. 2009;114(22):1422.
Voorhees PM, Gasparetto C, Richards KL, Garcia R, Strader JS, Ferraro M, MacLean J, Winans D, Moore DT, Hurd DD, et al. Vorinostat in combination with pegylated liposomal doxorubicin and bortezomib for patients with relapsed/refractory multiple myeloma: results of a phase I study [abstract]. Blood. 2009;114(22):129-130.
Keung Y, Beaty MW, Pettenati M, Levitan D, Molnar I, Thakuri M, Cruz J, Hurd DD. Possible role of engraftment syndrome in myelodysplastic syndrome after autologous transplants [abstract]. J Clin Oncol. 2008;26(Suppl):a18016.
Ferrans CE, Ryan C, Archer LE, Freels S, Lan L, Paskett E, Molokie R, Hurd DD, Kornblith AB. Factors contributing to cancer screening in African Americans [abstract]. J Clin Oncol. 2008;26(Suppl):a6514.
Giralt S, Mangan K, Maziarz R, Bubalo JS, Beveridge R, Hurd DD, Mendoza F, Rubenstein EB, DeGroot TJ, Schuster MW. Palonosetron (PALO) for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose melphalan prior to stem cell transplant (SCT) [abstract]. J Clin Oncol. 2008;26(Suppl):a9617.
Powell B, D'Agostino R Jr, Levitan D, Ellis LR, Lyerly S, Skiles M, Manuel M, Harrelson R, Kimbrough C, Hurd DD. High dose cytarabine and clofarabine (HiDAC-->CLOF) in relapsed or refractory acute myeloid leukemia, a phase 2 trial [abstract]. Blood. 2008;112(11):676.
Fehniger TA, Larson S, Trinkaus K, Siegal MJ, DiPersio JF, Cashen AF, Hurd DD, Blum KA, Bartlett NL. A phase II multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgin Lymphoma (cHL): preliminary results [abstract]. Blood. 2008;112(11):899-900.
Keung YK, Beaty MW, Pettenati M, Levitan D, Molnar I, Thakuri MC, Cruz J, Hurd DD. Possible role of engraftment syndrome in myelodysplastic syndrome after autologous transplants [abstract]. Blood. 2008;112(11):751.
Danhauer SC, Vishnevsky T, McCoy TP, Campbell CR, Tooze JA, Kanipe KN, Arrington SA, Lynch MB, Hurd DD, Cruz J, et al. Music for patients with hematological malignancies undergoing bone marrow biopsy: a randomized controlled study of effects on anxiety, perceived pain, and patient satisfaction [abstract]. J Soc Integr Oncol. 2008;6(4):190.
Molnar I, Stark N, Lovato J, Powell BL, Cruz J, Hurd DD, Mathieu JS, Cambra S, McQuellon RP, Schwartz GG, et al.
Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000-4000 IU vitamin D(3)) [letter]. Leukemia. 2007;21(5):1089-1092.
Schuster MW, Mehta J, Waller EK, Rifkin RM, Micallef I, Hurd D, Parekh S, Hari P, Skikne BS, Shea TC, et al. A randomized placebo controlled phase II trial of prevention of severe oral mucositis using single dose velafermin in patients receiving myeloablative therapy and autologous hematopoietic stem cell transplant (AHSCT) [abstract]. Blood. 2007;110(11 Pt 1):190A.
Spielberger R, Territo M, Durrant S, Nimer S, McCarty J, Hurd D, Berger D, Aycock J, Chen M-G, Stiff P. No difference in survival or long-term disease outcomes in palifermin-treated patients with hematologic malignancies undergoing hematopoietic stem cell transplantation [abstract]. Blood. 2007;110(11 Pt 1):496A.
Storey JA, Connor R, Lewis ZT, Lovato J, Hurd D, Torti FM, Molnar I. The transfusion iron overload score is a potential predictor of survival in stem cell transplant patients [abstract]. Blood. 2007;110(11 Pt 1):336A.
Casale DA, Bartlett NL, Hurd DD, Foss F, Pro B, Sokol L, Lieberman R, Luz H. A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma/leukemia [abstract]. Blood. 2006;108(11 Pt 1):771a.
Gupta P, Sanford BL, Yu D, Vij R, Hurd DD, Odenike O, Bloomfield CD, Hasserjian RP, Larson RA. A phase II study of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukemia Group B Study 10105 [abstract]. Blood. 2006;108(11 Pt 1):753a.
Damon LE, Johnson J, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Byrd JC, Kelly M, Linker C, Canellos GP. Immuno-chemotherapy (IC) and autologous stem cell transplantation (ASCT) for untreated patients (pts) with mantle cell lymphoma (MCL): CALGB 59909 [abstract]. Blood. 2006;108(11 Pt 1):774a.
Powell BL, Lovato J, Kimbrough C, Lyerly S, Galloway-Daniels S, Harrelson R, Keung YK, Thakuri MC, Molnar I, Levitan D, Hurd DD, et al. Limited phase I trial of sequential high dose cytarabine and clofarabine (HiDAC-->CLOF) in relasped or refractory acute myeloid leukemia [abstract]. Blood. 2006;108(11 Pt 2):221b.
All Publications
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.